IP Library Granted Patent US 7,193,044
Granted Patent B1
US 7,193,044 · App. 09/580,523 · Granted Mar 20, 2007

Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis

Assignee: Immunogen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,193,044
App. No.
09/580,523
Granted
Mar 20, 2007
Kind
B1
Abstract

Novel forms of mutant BAD polypeptides or fragments thereof having amino acid substitutions for serine-155 are provided along with their encoding polynucleotides. Also disclosed are methods for preparation of the mutant BAD polypeptides, methods for screening candidate compounds and drugs for activity that promotes cell survival or apoptosis, methods for screening candidate compounds and drugs for phosphatase activity capable of dephosphorylating BAD, methods for screening candidate compounds and drugs for kinase activity capable of phosphorylating BAD, methods for screening candidate compounds and drugs for activity that promotes phosphorylation of BAD, anti-BAD antibodies, and methods for inhibiting and inducing apoptosis.

Claims (22)

1. An isolated polypeptide comprising amino acids 103–123 of SEQ ID NO:1, wherein:

(a) serine-118 is replaced with alanine or glycine;

(b) said polypeptide has at least 85% sequence identity with SEQ ID NO: 1; and

(b) said polypeptide has in vitro cell death promoting activity.

2. The isolated polypeptide of claim 1 , wherein said polypeptide has at least 90% sequence identity with SEQ ID NO:1.

3. The isolated polypeptide of claim 1 , wherein said polypeptide has at least 95% sequence identity with SEQ ID NO:1.

4. The isolated polypeptide of any one of claims 1 , 2 , or 3 , wherein said serine-118 is replaced with alanine.

5. The isolated polypeptide of any one of claims 1 , 2 , or 3 , wherein said serine-118 is replaced with glycine.

6. An isolated polypeptide comprising amino acids 106–132 of SEQ ID NO:1, wherein:

(a) serine-118 is replaced with alanine or glycine;

(b) said polypeptide has at least 85% sequence identity with SEQ ID NO: 1; and

(b) said polypeptide has in vitro cell death promoting activity.

7. The isolated polypeptide of claim 6 , wherein said polypeptide has at least 90% sequence identity with SEQ ID NO:1.

8. The isolated polypeptide of claim 6 , wherein said polypeptide has at least 95% sequence identity with SEQ ID NO:1.

9. The isolated polypeptide of any one of claims 6 , 7 or 8 , wherein said serine-118 is replaced with alanine.

10. The isolated polypeptide of any one of claims 6 , 7 or 8 , wherein said serine-118 is replaced with glycine.

11. An isolated polypeptide comprising SEQ ID NO:1, except that serine-118 is replaced with alanine or glycine.

12. The isolated polypeptide of claim 11 , wherein serine-118 is replaced with alanine.

13. The isolated polypeptide of claim 11 , wherein serine-118 is replaced with glycine.

14. An isolated polypeptide consisting of SEQ ID NO:1, except that serine-118 is replaced with alanine or glycine.

15. The isolated polypeptide of claim 14 , wherein serine-118 is replaced with alanine.

16. The isolated polypeptide of claim 14 , wherein serine-118 is replaced with glycine.

Assignments (6)
ADDRESS CHANGE Recorded May 13, 2008
From: IMMUNOGEN, INC.
To: IMMUNOGEN, INC.
Reel/Frame 020930/0905 →
CORRECTIVE ASSIGNMENT TO CORRECT THE STATE AND ATTY. DOCKET NO. PREVIOUSLY RECORDED ON REEL 018500 FRAME 0526. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMETN FOR DETAILS). Recorded Nov 17, 2006
From: ZHOU, XIAO-MAI
To: APOPTOSIS TECHNOLOGY, INC.
Reel/Frame 018534/0451 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTY. DOCKET NO. PREVIOUSLY RECORDED ON REEL 018501 FRAME 0685. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER (SEE DOCUMENT FOR DETAILS).. Recorded Nov 13, 2006
From: APOPTOSIS TECHNOLOGY, INC.
To: IMMUNOGEN, INC.
Reel/Frame 018508/0307 →
MERGER Recorded Nov 9, 2006
From: APOPTOSIS TECHNOLOGY, INC.
To: IMMUNOGEN, INC.
Reel/Frame 018499/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2006
From: ZHOU, XIAO-MAI
To: APOPTOSIS TECHNOLOGY, INC.
Reel/Frame 018500/0526 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNEE ADDRESS NEEDS TO BE UPDATED. PLEASE CHANGE THE STATE FROM MARYLAND TO MASSACHUSETTS. PREVIOUSLY RECORDED ON REEL 018499 FRAME 0671. ASSIGNOR(S) HEREBY CONFIRMS THE THE ASSIGNEE ADDRESS NEEDS TO BE UPDATED. PLEASE CHANGE THE STATE FROM MARYLAND TO MASSACHUSETTS.. Recorded Nov 9, 2006
From: APOPTOSIS TECHNOLOGY, INC.
To: IMMUNOGEN, INC.
Reel/Frame 018501/0685 →